Previous 10 | Next 10 |
Delcath Systems Announces up to $85 Million Financing PR Newswire Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million fi...
2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Interventional oncology company Delcath Systems ( NASDAQ: DCTH ) said its board has appointed John Sylvester chairman. Sylvester has served as a director at the company since July 2019, and most recently served as CEO of both Curium's SPECT and International business units. C...
Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch PR Newswire NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventio...
Delcath Systems ( NASDAQ: DCTH ) announced Tuesday the company resubmitted a new drug application (NDA) to the FDA, seeking approval for the drug delivery device HEPZATO Kit as a treatment for certain patients with hepatic-dominant metastatic ocular melanoma. HEPZATO Kit is desig...
Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit PR Newswire NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of...
Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 PR Newswi...
Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology PR Newswire Updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29....
Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) PR Newswire NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic can...
Delcath Systems Closes Private Placement of $6.2 Million PR Newswire NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today a...
News, Short Squeeze, Breakout and More Instantly...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 5, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024...
2024-07-16 23:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 07:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...